|
61
|
247
|
2vinA |
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator |
|
58
|
247
|
2vivA |
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator |
|
60
|
247
|
2vipA |
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator |
|
58
|
247
|
2vioA |
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator |
|
56
|
247
|
2r2wU |
Urokinase plasminogen activator b-chain-gppe complex |
|
52
|
245
|
2o8tA |
Crystal structure and binding epitopes of urokinase-type plasminogen activator (c122a/n145q) in complex with inhibitors |
|
57
|
245
|
2o8wA |
Crystal structure and binding epitopes of urokinase-type plasminogen activator (c122a/n145q/s195a) in complex with inhibitors |
|
53
|
245
|
2o8uA |
Crystal structure and binding epitopes of urokinase-type plasminogen activator (c122a/n145q/s195a) in complex with inhibitors |
|
56
|
246
|
2nwnA |
New pharmacophore for serine protease inhibition revealed by crystal structure of human urokinase-type plasminogen activator complexed with a cyclic peptidyl inhibitor, upain-1 |
|
24
|
122
|
2i9bA |
Crystal structure of atf-urokinase receptor complex |
|
30
|
123
|
2i9aA |
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (atf) |
|
25
|
122
|
2fd6A |
Structure of human urokinase plasminogen activator in complex with urokinase receptor and an anti-upar antibody at 1.9 a |
|
56
|
247
|
1w14U |
Urokinase type plasminogen activator |
|
59
|
247
|
1w11U |
Urokinase type plasminogen activator |
|
59
|
247
|
1w0zU |
Urokinase type plasminogen activator |
|
56
|
247
|
1w12U |
Urokinase type plasminogen activator |
|
56
|
247
|
1w13U |
Urokinase type plasminogen activator |
|
58
|
247
|
1w10U |
Urokinase type plasminogen activator |
|
57
|
247
|
1vjaU |
Urokinase plasminogen activator b-chain-jt463 complex |
|
57
|
247
|
1vj9U |
Urokinase plasminogen activator b-chain-jt464 complex |
|
10
|
130
|
1urkA |
Solution structure of the amino terminal fragment of urokinase-type plasminogen activator |
|
49
|
245
|
1u6qA |
Substituted 2-naphthamadine inhibitors of urokinase |
|
57
|
245
|
1sqoA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
55
|
245
|
1sqaA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
58
|
245
|
1sqtA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
57
|
247
|
1sc8U |
Urokinase plasminogen activator b-chain-j435 complex |
|
48
|
245
|
1owjA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
60
|
245
|
1owhA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
58
|
245
|
1oweA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
58
|
245
|
1owdA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
50
|
245
|
1owiA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
49
|
245
|
1owkA |
Substituted 2-naphthamidine inhibitors of urokinase |
|
52
|
246
|
1o3pB |
Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors |
|
0
|
9
|
1o5cA |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
0
|
8
|
1o5bA |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
0
|
8
|
1o3pA |
Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors |
|
54
|
246
|
1o5cB |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
52
|
246
|
1o5aB |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
0
|
9
|
1o5aA |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
49
|
245
|
1o5bB |
Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) |
|
0
|
8
|
1lmwA |
Lmw u-pa structure complexed with egrcmk (glu-gly-arg chloromethyl ketone) |
|
38
|
248
|
1lmwB |
Lmw u-pa structure complexed with egrcmk (glu-gly-arg chloromethyl ketone) |
|
5
|
85
|
1kduA |
Sequential 1h nmr assignments and secondary structure of the kringle domain from urokinase |
|
1
|
13
|
1gjdA |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
|
1
|
13
|
1gjaA |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
|
52
|
245
|
1gi8B |
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site |
|
51
|
246
|
1gjcB |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
|
0
|
10
|
1gj7A |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
|
50
|
246
|
1gjbB |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
|
1
|
13
|
1gj8A |
Engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets |
